

Croda opens advanced lipids manufacturing facility in Pennsylvania

15 January 2025: Croda International Plc (“Croda”), the company that uses smart science to create high-performance ingredients and solutions that improve lives, today announces the opening of a pioneering new lipids manufacturing facility in Lamar, Pennsylvania, USA. Our investment in this new site reinforces Croda’s commitment to drive innovation in drug delivery systems for next-generation therapeutics.

This state-of-the-art facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’, continuing collaborative efforts to support the development and commercialisation of next-generation therapies. The new 23,680 square foot, multi-purpose facility will enhance Croda’s capabilities in producing critical components for drug delivery systems, including lipids used for delivery of nucleic acid-based therapeutics, mRNA vaccines, gene editing therapies, and novel cancer treatments. As the pharmaceutical industry accelerates innovation in biologics, our Lamar facility will play a key role in supporting advancements that improve global health outcomes.

David Cherry, Interim President Life Sciences said: “Opening this facility demonstrates our commitment to advancing health through innovation and collaboration.

“By expanding our lipid manufacturing capabilities, we are not only meeting the growing demands of the pharmaceutical industry, but we are also ensuring we are prepared to support future public health emergencies, all while remaining true to our Purpose of improving lives through smart science.”

Croda’s Lamar facility is the result of a strategic collaboration with the Administration for Strategic Preparedness and Response’s Biomedical Advanced Research and Development Authority (BARDA), and significantly enhances the domestic manufacturing capacity in the USA for vital drug delivery systems – including the production of lipids that played a key role in the success of COVID-19 vaccines.

Bradley Cook, Vice President, North American Operations commented: “There are rare moments when a team can contribute to the advancement in healthcare for the benefit of society. Our collaboration with BARDA and other agencies has positioned us to support the discovery and delivery of life-changing therapeutics.”

This new facility complements our Alabaster site in Alabama, formerly known as the Avanti Polar Lipids site, and other locations outside of the North American region, in Leek, UK, and Iksan, Korea. Together, these sites build on Croda’s proven track record supporting critical public health initiatives, including the scale up of lipids for the delivery of mRNA COVID-19 vaccines during the pandemic. Croda’s expanded Good Manufacturing Practices (GMP) capabilities, including the Lamar facility, continues this legacy, reinforcing Croda as a leader in the development, manufacturing and commercialisation of lipid-based materials for cutting-edge therapies.

The Lamar facility, part of a 37-acre multipurpose cGMP complex acquired in 2021, will support the local community creating around 50 new jobs, spanning engineering, administration, maintenance, operations, and logistics. Designed with sustainability in mind,

the site aligns with Croda's long-term environmental goals, ensuring responsible and efficient manufacturing practices.

ENDS

For more information, please contact:

Mariana Wood, Croda International Plc. press office

Email: media.enquiries@croda.com

Contact: +44 7780 987136

Alexandra Inglis, Croda Pharma press office

Email: alexandra.inglis@croda.com

Contact: +1 732 666 8091

About Croda

Croda is a specialty chemicals company that creates high performance ingredients and solutions principally for Consumer Care and Life Sciences markets. Established 100 years ago in 1925 and headquartered in the UK, Croda is a FTSE 100 company with over 5,800 employees across 92 locations in 39 countries. Revenues in 2023 were £1.69bn.

As the name behind some of the world's most successful brands, we combine our knowledge, passion and entrepreneurial spirit to develop and supply innovative ingredients relied on by industries and consumers around the world. Our smart science is found in products that touch our lives every day from sun protection to life-saving pharmaceuticals and formulations that enhance crop yields.

With a shared Purpose to use Smart science to improve lives™, and with around two thirds of its organic raw materials already from bio-based sources, Croda has committed to be the most sustainable supplier of innovative ingredients, becoming Climate, Land and People Positive by 2030 while providing solutions to some of the world's biggest challenges.

To find out more about Croda visit: www.croda.com

About Croda Pharma

Croda's Pharma business is a leading partner in the development of excipients and the supply of high purity materials for pharmaceutical formulations and is committed to enabling the next generation of drug delivery systems. The business is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid delivery platforms.

To find out more about Croda Pharma visit: www.crodapharma.com

About Avanti Research

Avanti Research, a Croda brand, creates highly purified lipids, ingredients and services for pharmaceutical and fundamental research, and diagnostics. With a catalogue comprising over 2,000 lipids, Avanti Research also offers custom lipid synthesis and formulation development.

Avanti Research is a trademark of Croda International Plc. Avanti Research is a Croda brand associated with Avanti Polar Lipids, LLC

To find out more about Avanti Research visit: www.avantiresearch.com

The project described in this press release has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority under award number 1 IDSEP230066-01.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority.